New strategies for the prevention and treatment of Helicobacter pylori infection

Bibliography

• MARSHALL BJ, WARREN JR.: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 1(8390):1311–1315.
   Google Scholar
• GOODWIN CS, ARMSTRONG JA, MARSHALL BJ: Carnpylobacter pyloridis, gastritis, and peptic ulceration. j. Pathol (1986) 39:353–365.
   Web of Science ®Google Scholar
• FOX JG: The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases. Gut (2002) 50:273–283.
   PubMed Web of Science ®Google Scholar
• •An updated review which describes the hitherto known Helicobacter species other than H pylori
   Google Scholar
• TINDBERG J, BENGTSSON C, GRANATH F, BLENNOW M, NYREN 0, GRANDSTROM M: Helicobacter pylori infection in a Swedish school children: lack of evidence of child-to-child transmission outside the family. Gastroenterology (2001) 121:310–316.
   PubMed Web of Science ®Google Scholar
• •A formal demonstration of H pylori transmission within the family.
   Google Scholar
• EL-ZAATARI FAK, WOO JS, BADR A et al.: Failure to isolate Helicobacter pylori from stray cats indicates that H pyloriin cats may be an anthroponosis - an animal infection with a human pathogen. I Med. Microbiol (1997) 46:372–376.
   PubMed Web of Science ®Google Scholar
• BROWN LM, THOMAS TL, MA JL et al: Helicobacter pyloriinfection in rural China: exposure to domestic animals during childhood and adulthood. Scand. I Infect. Dis. (2001) 33:686–691.
   PubMed Web of Science ®Google Scholar
• SINHA SK, MARTIN B, SARGENT M, McCONNELL JP, BERNSTEIN CN: Age at acquisition of Helicobacter pylori in a pediatric Canadian First Nations population. Helicobacter (2002) 7:76–85.
   PubMed Web of Science ®Google Scholar
• SAVARINO V, VIGNERI S, CELLE G: The I-3C urea breath test in the diagnosis of Helicobacter pyloriinfection. Gut (1999) 45 (Supp1.1): 118:122.
   Google Scholar
• DUNN BE, COHEN H, BLASER MJ: Helicobacter pylori Clin. Microbiol Rev (1997) 10:720–741.
   Google Scholar
• HERBRINK P, VAN DOORN LJ: Serological methods for diagnosis of Helicobacter pyloriinfection and monitoring of eradication therapy. Ear: j Clin. Microbiol Infect. Dis. (2000) 19:164–173.
   PubMed Web of Science ®Google Scholar
• VAIRA D, HOLTON J, MENEGATTI M et al.: Invasive and non-invasive tests for Helicobacter pylori infection. Aliment. Pharmacol Ther. (2000) 14(Suppl.)3:13–22.
   Google Scholar
• GISBERT JP, PAJARES JM: Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review. Am. Gastroenterol (2001) 96:2829–2838.
   PubMed Web of Science ®Google Scholar
• VAIRA D, VAKIL N, MENEGATTI M et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann. Intern. Med. (2002) 136:280–287.
   PubMed Web of Science ®Google Scholar
• XIA HH, TALLEY NJ: Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am. j Gastroenterol (2001) 96:16–26.
   PubMed Web of Science ®Google Scholar
• DORE MP, GRAHAM DY: Pathogenesis of duodenal ulcer disease: the rest of the story. Baillieres Best Pract. Res. Clin. Gastroenterol (2000) 14:97–107.
   PubMed Web of Science ®Google Scholar
• APPELMELK BJ, NEGRINI R, MORAN AP, KUIPERS EJ: Molecular mimicry between Helicobacter pylori and the host. Trends Microbiol (1997) 5:70–73.
   PubMed Web of Science ®Google Scholar
• SONTAG SJ: Guilty as charged: bugs and drugs in gastric ulcer. Am. j Gastroenterol (1997) 92:1255–1261.
   PubMed Web of Science ®Google Scholar
• DU MQ, ISACCSON PG: Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol (2002) 3:97–104.
   PubMed Web of Science ®Google Scholar
• WOTHERSPOON AC, ORTIZ-HIDALGO C, FALZON MR, ISAACSON PG: Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet (1991) 338(8776):1175–1176.
   PubMed Web of Science ®Google Scholar
• UEMURA N, OKAMOTO S, YAMAMOTO S et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl. J. Med. (2001) 345:784–789.
   PubMed Web of Science ®Google Scholar
• •A formal demonstration of necessity of H pylori in the development of gastric cancer.
   Google Scholar
• FORMAN D, WEBB P, PARSONNET J: Helicobacter pylori and gastric cancer. Lancet (1994) 343:243–244.
   PubMed Web of Science ®Google Scholar
• OGURA K, MAEDA S, NAKAO M et al.: Virulence factors of Helicobacter pylori responsible for gastric diseases in mongolian gerbil. .1 Exp. Med. (2000) 192:1601–1609.
   Google Scholar
• •Demonstration of the essential role of cag pathogenicity island for induction of ulcer and cancer in experimental animals.
   Google Scholar
• WATANABE T, TADA M, NAGAI H, SASAKI S, NAKAO M. Helicobacter pylori induces gastric cancer in Mongolian gerbils. Gastroenterology (1998) 115:642–648.
   PubMed Web of Science ®Google Scholar
• HAN SU, KIM YB, J00 HJ et al.: Helicobacter pylori infection promotes gastric carcinogenesis in a mice model. j. Gastroenterol Hepatol (2002) 17:253–261.
   Google Scholar
• BARIOL C, FIELD A, VICKERS CR, WARD R: Regression of gastric T cell lymphoma with eradication of Helicobacter pylori Gut (2001) 48:269–271.
   Google Scholar
• HANSSON LE, NYREN 0, HSING AW et al.: The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl. J. Med. (1996) 335:242–249.
   Google Scholar
• COVACCI A, RAPPUOLI R: Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J. Exp. Med. (2000) 191:587–592.
   PubMedGoogle Scholar
• CENSINI S, LANGE C, XIANG Z et al:cag, a pathogenicity island of Helicobacter pylori, encodes Type I-specific and disease-associated virulence factors. Proc. Nat] Acad. Sci. USA (1996) 93:14648–14653.
   PubMed Web of Science ®Google Scholar
• PARSONNET J, FRIEDMAN GD, ORENTREICH N, VOGELMAN H: Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut (1997) 40:297–301.
   PubMed Web of Science ®Google Scholar
• COVACCI A, TELFORD JL, DEL GIUDICE G, PARSONNET J, RAPPUOLI R: H py/orivirulence and genetic geography. Science (1999) 284:1328–1333.
   PubMed Web of Science ®Google Scholar
• •This review evidences links between H pylori and disease, and outlines a co-evolution of the bacterium with man.
   Google Scholar
• SUNG JJ, LIN SR, CHING JY, ZHOU LY, TO KF, WANG RT: Atrophy and intestinal metaplasia one year after cure of H pylori infection: a prospective, randomized study. Gastroenterology (2000) 119:7–14.
   PubMed Web of Science ®Google Scholar
• PAPA A, CAMMAROTA G, TURSI A, GASBARRINI A, GASBARRINI G: Helicobacter pylori eradication and remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma: a long-term follow-up study. Clin. Gastroenterol (2000) 31:169–171.
   Google Scholar
• ISAACSON PG: Gastric MALT lymphoma: from concept to cure. Ann. Oncol (1999) 10:637–645.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA T, SAKAKI N, KOZAWA H et al.: Sensitivity of biopsy site in evaluating regression of gastric atrophy after H pylori eradication treatment. Aliment. Pharmacol Then. (2002) 16\(Suppl. 2):187–190.
   Google Scholar
• KIM N, LIM SH, LEE KH et al: Long-termeffects of H pylori eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers. Dig. Dis. Sci. (2000) 45:1754–1762.
   PubMed Web of Science ®Google Scholar
• FRENDRICK AM, CHERNEW ME, HIRT RA, BLOOM BS, BANDEKAR RR, SCHEIMAN JM: Clinical and economic effects of population-based H pylori screening to prevent gastric cancer. Arch. Intern. Med. (1999) 159:142–148.
   PubMed Web of Science ®Google Scholar
• MASON J, AXON AT, FORMAN D et al: The cost-effectiveness of population H pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment. Pharmacol Ther. (2002) 16:559–568.
   PubMed Web of Science ®Google Scholar
• IKEDA S, TAMAMURO T, HAMASHIMA C, ASAKA M: Evaluation of the cost-effectiveness of H pylori eradication triple therapy versus conventional therapy for ulcers in Japan. Ailment. Pharmacol The]: (2001) 15:1777–1785.
   Google Scholar
• MOAYYEDI P, SOO S, DEEKS J et al: Systematic review and economic evaluation of H pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ(2000) 321(7262):659–664.
   PubMed Web of Science ®Google Scholar
• SCHWIZER W, THUMSHIRN M, DENT J et al.: H pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet (2001) 357(9270):1738–1742.
   PubMed Web of Science ®Google Scholar
• DATTILO M, FIGURA N: H. pylori infection, chronic gastritis, and proton pump inhibitors. J Clin. Castroenterol (1998) 27\(Suppl. 1):5163–9.
   Google Scholar
• GISBERT JP, MARCOS S, GISBERT JL, PAJARES JM: High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in H py/orieradication. Helicobacter (2001) 6:81–83.
   PubMed Web of Science ®Google Scholar
• HSIEH YH, LIN HJ, TSENG GY, PERNG CL, CHANG FY, LEE SD: A 3-day anti-H pylori therapy is a good alternative for bleeding peptic ulcer patients with H pylori infection: Hepatogastroenterology (2001) 48:1078–1081.
   Google Scholar
• CALVET X, GENE E, LOPEZ T, GISBERT JP: What is the optimal length of proton pump inhibitor-based triple therapies for H pylon? A cost-effectiveness analysis. Aliment. Pharmacol The]: (2001) 15:1067–1076.
   PubMed Web of Science ®Google Scholar
• MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of H pylori infection - the Maastricht 2–2000 Consensus Report. Ailment. Pharmacol Then. (2002) 16:167–180.
   Google Scholar
• DAJANI EZ, KLAMUT MJ: Novel therapeutic approaches to gastric and duodenal ulcers: an update. Expert Opin. Investig. Drugs (2000) 9(7):1537–1544. This review contains an exhaustive section on PPIs.
   Google Scholar
• BREUER T, GRAHAM DY: Cost of diagnosis and treatment of H pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am. Castroenterol (1999) 94:725–729.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, PAJARES JM: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. A review. Ailment. Pharmacol The]: (2002) 16:1047–1057.
   PubMed Web of Science ®Google Scholar
• DE BOER WA: A novel therapeutic approach for H py/oriinfection: the bismuth-based triple therapy monocapsule. Expert Opin. Investig. Drugs (2001) 10:1559–1566.
   PubMed Web of Science ®Google Scholar
• SCOTT LJ, DUNN CJ, MALLARKEY G, SHARPE M: Esomeprazole: A review of its use in the management of acid-related disorders in the US. Drugs (2002) 62:1091–1118.
   PubMed Web of Science ®Google Scholar
• LI H, CHUNG SJ, KIM DC, KIM HS, LEE JW, SHIM CK: The transport of a reversible proton pump antagonist, 5,6-dimethyl 2 (4 fluorophenylamino) 4 (1 methyl-1, 2, 3,4-tetrahydroisoquinoline-2-34) pyrimidine hydrochloride (YH1885), across Caco-2 cell monolayers. Drug Metab. Dispos. (2001) 29:54–59.
   PubMed Web of Science ®Google Scholar
• ANKLI A, HEINRICH M, BORK P et al.: Yucatec Mayan medicinal plants: evaluation based on indigenous uses. j. Ethnopharmacol (2002) 79:43–52.
   PubMed Web of Science ®Google Scholar
• MALEKZADEH F, EHSANIFAR H, SHAHAMAT M, LEVIN M, COLWELL RR: Antibacterial activity of black myrobalan (Terminalia chebula Retz) against H pylon. Int. j Antimicrob. Agents (2001) 18:85–88.
   PubMed Web of Science ®Google Scholar
• GADHI CA, BENHARREF A, JANA M, LOZNIEWSKI A: Anti-H pylori activity of Aristolochia paucinervisPomel extracts. Ethnopharmacol (2001) 75:203–205.
   PubMed Web of Science ®Google Scholar
• BURGER 0, OFEK I, TABAK M, WEISS El, SHARON N, NEEMAN I: A high molecular mass constituent of cranberry juice inhibits H pylon adhesion to human gastric mucus. FEMS Immunol Med. Microbiol (2000) 29:295–301.
   PubMed Web of Science ®Google Scholar
• YESILADA E, GURBUZ I, SHIBATA H: Screening of Turkish anti-ulcerogenic folk remedies for anti-H pylori activity. Ethnopharmacol (1999) 66:289–293.
   PubMed Web of Science ®Google Scholar
• KALPOUTZAKIS E, ALIGIANNIS N, MENTIS A, MITAKU S, CHARVALA C: Composition of the essential oil of two Nepeta species and In vitro evaluation of their activity against H pylori Planta Med. (2001) 67:880–883.
   Google Scholar
• BAE EA, HAN MJ, BAEK NI, KIM DH: In vitro anti-H pylori activity of panaxytriol isolated from ginseng. Arch. Pharm. Res. (2001) 24:297–299.
   PubMed Web of Science ®Google Scholar
• HAMASAKI N, ISHII E, TOMINAGA K et al.: Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Nu-Chu-Yu), against H. pylori in vitro. Microbiol Immunol (2000) 44:9–15.
   PubMed Web of Science ®Google Scholar
• RHO TC, BAE EA, KIM DH, OH WK, KIM BY, AHN JS, LEE HS: Anti-H pylori activity of quinolone alkaloids from Evodiae fructus. Biol. Pharm. Bull. (1999) 22:1141–1143.
   PubMed Web of Science ®Google Scholar
• KATAOKA M, HIRATA K, KUNIKATA T et al.: Antibacterial action of tryptanthrin and kaempferol, isolated from the indigo plant (Polygonum tinctorium Lour.), against H pylori-infected Mongolian gerbils. Castroenterol (2001) 36:5–9.
   Web of Science ®Google Scholar
• MAHADY GB, MATSUURA H, PENDLAND SL: Allixin, a phytoalexin from garlic, inhibits the growth of H pylori In vitro. Am. .1 Castroenterol (2001) 96:3454–3455.
   Google Scholar
• MCNULTY CA, WILSON MP, HAVINGA W, JOHNSTON B, O'GARA EA, MASLIN DJ: A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with H pylori Helicobacter (2001) 6:249–253.
   Google Scholar
• SHIRATAKI Y, MOTOHASHI N, TANI S et al.: Antioxidative activity of Album victorialisL. extracts. Anti-Cancer Res. (2001) 21:3331–3339.
   PubMedGoogle Scholar
• BRENNER H, ROTHENBACHER D, BODE G, ADLER G: Inverse graded relation between alcohol consumption and active infection with H pylon. Am. Epidemiol (1999) 149:571–576.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK SJ, JORGENSEN T, ANDERSON LP, BONNEVIE 0: Association of H py/oriinfection with lifestyle, chronic disease, body-indices, and age at menarche in Danish adults. Scand. Public Health (2000) 28:32–40.
   PubMed Web of Science ®Google Scholar
• BUJANDA L: The effect of alcohol consumption upon the gastrointestinal tract. Am. J. Castroenterol (2000) 95:3374–3382.
   PubMed Web of Science ®Google Scholar
• DAROCH F, HOENEISEN M, GONZALEZ CL et al.: In vitro antibacterial activity of Chilean red wines against H pylori Microbios (2001) 104:79–85.
   Google Scholar
• BAE EA, HAN MJ, KIM DH: In vitro anti- H pylori activity of irisolidone isolated from the flowers and rhizomes of Pueraria thunbergiana. Planta Med. (2001) 67:161–163.
   PubMed Web of Science ®Google Scholar
• YOSHIDA T, HATANO T, ITO H: Chemistry and function of vegetable polyphenols with high molecular weights. Bio factors (2000) 13:121–125.
   PubMed Web of Science ®Google Scholar
• BANSKOTA AH, TEZUKAY, ADNYANA IK et al: Hepatoprotective and anti-H pylori activities of constituents from Brazilian propolis. Phytomedicine (2001) 8:16–23.
   PubMed Web of Science ®Google Scholar
• YEE YK, KOO MW: Anti-H pylori activity of Chinese tea: in vitro study. Aliment. Pharmacol. Then. (2000) 14:635–638.
   PubMed Web of Science ®Google Scholar
• BAE EA, HAN MJ, KIM DH: In vitro anti-H pylon activity of some flavonoids and their metabolites. Planta Med. (1999) 65:442–443.
   PubMed Web of Science ®Google Scholar
• ANNUK H, HIRMO S, TURI E, MIKELSAAR M, ARAK E, WADSTROM T: Effect on cell surface hydrophobicity and susceptibility of H pylorito medicinal plant extracts. FEMS Microbiol. Lett. (1999) 172:41–45.
   PubMed Web of Science ®Google Scholar
• MEYER JM, SILLIMAN NP, WANG W et al.: Risk factors for H py/oriresistance in the United States: the surveillance of H pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann. Intern. Med. (2002) 136:13–24.
   PubMed Web of Science ®Google Scholar
• OSATO MS, REDDY R, REDDY SG, PENLAND RL, MALATY HM, GRAHAM DY: Pattern of primary resistance of H pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med. (2001) 161:1217–1220.
   PubMed Web of Science ®Google Scholar
• •The two papers above give a reliable evaluation of the H py/oriantibiotic resistance, examining a large number of patients.
   Google Scholar
• TORRES J, CAMORLINGA-PONCE M, PEREZ-PEREZ G et al.: Increasing multidrug resistance in H pylori strains isolated from children and adults in Mexico. .1. Clin. Microbiol. (2001) 39:2677–2680.
   Google Scholar
• YAKOOB J, FAN X, HU G, LIU L, ZHANG Z: Antibiotic susceptibility of H pylori in the Chinese population. Gastroenterol. Hepatol. (2001) 16:981–985.
   Web of Science ®Google Scholar
• KALACH N, BERGERET M, BENHAMOU PH, DUPONT C, RAYMOND J: High levels of resistance to metronidazole and clarithromycin in H py/oristrains in children. I Clin. Microbiol. (2001) 39:394–397.
   PubMed Web of Science ®Google Scholar
• DORE MP, KWON DK, SEPULVEDA AR, GRAHAM DY, REALDI G: Stable amoxycillin resistance in H pylori Helicobacter (2001) 6:79.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND P, BARDHAN P, ROSSI L et al: Recrudescence and reinfection with H pylori after eradication therapy in Bangladeshi adults. Gastroenterology (2001) 121:792–798.
   PubMed Web of Science ®Google Scholar
• DELLA LIBERA E, ROHR MR, MORAES M, SIQUEIRA ES, FERRARI AP Jr: Eradication of H pylori infection in patient with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates. Bnaz.j Med. Biol. Res. (2001) 34:753–757.
   PubMed Web of Science ®Google Scholar
• RAMIREZ-RAMOS A, GILMAN RH, LEON-BARUA R et al.: Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Clin. Infect. Dis. (1997) 25:1027–1031.
   PubMed Web of Science ®Google Scholar
• JEEN YT, LEE SW, KWON SI et al: Differentiation between reinfection and recrudescence of H pylori strains using PCR-based restriction fragment length polymorphism analysis. Yonsei Med. j (2001) 42:41–45.
   PubMed Web of Science ®Google Scholar
• FEIZ HR, MOBARHAN S: Does vitamin C intake slow the progression of gastric cancer in H pylori-infected populations? Num Rev (2002) 60:34–36.
   Google Scholar
• ZHANG ZW, ABDULLAHI M, FARTHING MJ; Effect of physiological concentrations of vitamin C on gastric cancer cells and H. pylori Gut (2002) 50:165–169.
   PubMed Web of Science ®Google Scholar
• EKSTROM AM, SERAFINI M, NYREN 0, HANSSON LE, YE W, WOLK A: Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. hat. Cancer (2000) 87:133–140.
   PubMed Web of Science ®Google Scholar
• SHIBATA K, MORIYAMA M, FUKUSHIMA T, KAETSU A, MIYAZAKI M, UNE H: Green tea consumption and chronic atrophic gastritis: a cross-sectional study in a green tea production village.' Epidennol. (2000) 10:310–316.
   Google Scholar
• SIMAN JH, FORSGREN A, BERGLUND G, FLOREN CH: Tobacco smoking increases the risk for gastric adenocarcinoma among Helicobacter pylori-infected individuals. Scand. Gastroenterol. (2001) 36:208–213.
   PubMed Web of Science ®Google Scholar
• MARSHALL BJ, AMSTRONG JA, MCGECHIE DB, GLANCY RJ: Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med. I Austr. (1985) 142:436–439.
   Google Scholar
• MORRIS A, NICHOLSON G: Ingestion of Campy/obacter py/oridis causes gastritis and raised resting gastric pH. Am. I Gastroenterol. (1987) 82:192–99.
   PubMed Web of Science ®Google Scholar
• SOBALA GM, CRABTREE JE, DIXON MF, SCHORAH CJ, TAYLOR JD: Acute H py/oriinfection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut (1991) 32:1415–1418.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, OPEKUN AR, OSATO MS, EL ZIMAITY HMT, CADOZ M: H py/orivaccine development in humans: challenge model. Third Annual Winter H pylori Workshop, Orlando, FL, USA (1999), Poster no. 54.
   Google Scholar
• LEE A, FOX JG, OTTO G, MURPHY J: A small animal model of human H pylon active chronic gastritis. Gastroenterology (1990) 99:1315–1323.
   PubMed Web of Science ®Google Scholar
• •This is the first reported animal model of infection with one Helicobacter species.
   Google Scholar
• FERRERO RL, LABIGNE A: Cloning, expression, and sequencing of H fells urease gene. Mol. Microbiol. (1993) 9:323–333.
   PubMed Web of Science ®Google Scholar
• MACCHIA G, MASSONE A, BURRONI D, COVACCI A, CENSINI S. RAPPUOLI R: The Hsp 60 of H pylon: structure and immune response in patients with gastroduodenal disease. Mol. Microbiol. (1993) 9:645–652.
   Google Scholar
• XIANG ZY, CENSINI S, BAYELI PF, TELFORD JL, FIGURA N: Analysis and expression of VacA and CagA virulence factors in 43 strains of H pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect. Inman. (1995) 63:94–98.
   PubMed Web of Science ®Google Scholar
• KARITA M, KOUCHIYAMA T, OKITA K, NAKAZAWA T: New small animal model for human gastric H py/oriinfection: success in both nude and euthymic mice. Am. Gastroenterol. (1991) 86:1596–1603.
   PubMed Web of Science ®Google Scholar
• CELLINI L, ALLOCATI N, ANGELUCCI D et al.: Coccoid H pylori not culturable in vitro reverts in mice. Microbiol. Immunol. (1994) 38:843–850.
   PubMed Web of Science ®Google Scholar
• MARCHETTI M, ARICO B, BURRONI D, FIGURA N, RAPPUOLI R, GHIARA P: Development of a mouse model of H pylori infection that mimics human disease. Science (1995) 267:1655–1658.
   PubMed Web of Science ®Google Scholar
• •The first model of experimental infection of immunocompetent mice with H
   Google Scholar
• GHIARA P, MARCHETTI M, BLASER BJ, TUMMURU MKR, COVER TL: Role of the H py/orivirulence factors vacuolating cytotoxin, CagA and urease in a mouse model of disease. Infect. Inman. (1995) 63:4154–4160.
   PubMed Web of Science ®Google Scholar
• GHIARA P, COVACCI A, TELFORD JL, RAPPUOLI R: H pylori pathogenic determinants and strategies for vaccine design. In: Concept in Vaccine Development. Kaufmann SHE (Ed.), Walter de Gruyter, Berlin/New York (1996):459–496.
   Google Scholar
• GHIARA P, ROSSI M, MARCHETTI M, DI TOMMASO A etal.: Therapeutic intragastric vaccination against H pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Inman. (1997) 65:4996–5002.
   Google Scholar
• LI H, KALIES I, MELLGARD B, HELANDER HF: A rat model of chronic H pylori infection. Studies of epithelial cell turnover and gastric ulcer healing. Scand. .1. Gastroenterol (1998) 33:370–378.
   PubMed Web of Science ®Google Scholar
• SHOMER NH, DANGLER CA, WHARY MT, FOX JG: Experimental H pylori infection induces antral gastritis and gastric mucosa-associated lymphoid tissue in guinea pigs. Infect. Inman. (1998) 66:2614–2618.
   PubMed Web of Science ®Google Scholar
• HIRAYAMA F, TAKAGI S, KUSUHARA H, IWAO E, YOKOYAMA Y, IKEDA Y: Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with H pylon. I Gastroenterol (1996) 31:755–757.
   PubMed Web of Science ®Google Scholar
• EATON KA, BROOKS CL, MORGAN DR, KRAKOWKA S: Essential role of urease in pathogenesis of gastritis induced by Helicobacter pyloriin gnotobiotic pigs. Infect. Inman. (1991) 59:2470–2475.
   PubMed Web of Science ®Google Scholar
• AKOPYANTS NS, EATON KA, BERG DE: Adaptive mutation and cocolonization during Helicobacter pylori infection of gnotobiotic piglets. Infect. Immun. (1995) 63:116–121.
   PubMed Web of Science ®Google Scholar
• DUBOIS A, BERG DE: The nonhuman primate model for H pykriinfection. In: Methods in Molecular Medicine, H pylori Protocols. Clayton CL, Mobley HTL (Ed.). Humana Press, Inc., Totowa, NJ, USA (1997):253–269.
   Google Scholar
• DUBOIS A, FIALA N, HAMAN-ACKAH LM, DRAZEK ES, TARNAWASKI A: Natural gastric infection with H pyloriin monkeys. Gastroenterology (1994) 106:1405–1417.
   PubMed Web of Science ®Google Scholar
• RADIN MJ, EATON KA, KRAKOWKA S, MORGAN DR, LEE A: H py/ori gastric infection in gnotobiotic Beagle dogs. Infect. Inman. (1990) 58:2606–2612.
   PubMed Web of Science ®Google Scholar
• ROSSI G, FORTUNA D, PANCOTTO L, RENZONI G, TACCINI E, GHIARA P etal.: Immunohistochemical study of the lymphocyte populations infiltrating the gastric mucosa of beagle dogs experimentally infected with H pylori. Infect. Inman. (2000) 68: 4769–4772.
   Google Scholar
• MORRIS A, NICHOLSON G: ingestion of Carnpylobacter pyloridis causes gastritis and raised resting gastric pH. Arm Gastroenterol (1987) 82:192–199.
   Web of Science ®Google Scholar
• DEL GIUDICE G, COVACCI A, TELFORD JL, MONTECUCCO C, RAPPUOLI R: The design of vaccines against Helicobacter pylori and their development Ann. Rev Immunol (2001) 19:523–563.
   Google Scholar
• •A comprehensive overview on the state of H py/orivaccine development; contains detailed tables about H py/orivaccine in animal models.
   Google Scholar
• LEE CK, WELTZIN R, THOMAS WD Jr, KLEANTHOUS H, ERMAK TH: Oral immunization with recombinant H pylori urease induces secretory IgA antibodies and protects mice from challenge with H fells. Infect.Dis. (1995) 172:161–162.
   Google Scholar
• FERRERO RL, THIEBERGE JM, LABIGNE A: Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterology(1997) 113:185–194.
   PubMed Web of Science ®Google Scholar
• TOSI MF, CZINN SJ: Opsonic activity of specific IgG against H pylori I Infect. Dis. (1990) 162:156–166.
   Google Scholar
• COVER TL, CAO P, MURPHY UK, SIPPLE MS, BLASER MJ: Serum neutralizing antibody response to the vacuolating cytotoxin of H pylon. I Clin. Invest. (1992) 90:913–918.
   PubMed Web of Science ®Google Scholar
• NEDRUD J, BLANCHARD T, CZINN S, HARRIMAN G: Orally-immunized deficient mice are protected against H fells infection. Gut (1996) 39\(Suppl. 2):A45.
   Google Scholar
• BOGSTEDT AK, NAVA S, WADSTROM T, HAMMARSTROM L: H py/oriinfection in IgA deficiency: lack of role for the secretory immune system. Clin. Exp. Immunol (1996) 105:202–204.
   PubMed Web of Science ®Google Scholar
• ERMAK TH, GIANNASCA PJ, NICHOLS R, MYERS GA, NEDRUD J, WELTZIN R: Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC Class II-restricted responses. J. Exp. Med. (1998) 188:2277–2288.
   PubMed Web of Science ®Google Scholar
• RADCLIFF FJ, RAMSAY AJ, LEE A: Failure of immunization against Helicobacter infection in IL-4 deficient mice: evidence for a Th2 immune response as the bias for protective immunity. Gastroenterology (1996) 110:A997.
   Web of Science ®Google Scholar
• MICHETTI P, KREISS C, KOTLOFF K etal.: Oral immunization with urease and Escherichia cob heat-labile enterotoxin is safe and immunogenic in H pylori-infected adults. Gastroenterology (1999) 116:804–812.
   Google Scholar
• DI PETRILLO MD, TIBBETTS T, KLEANTHOUS H, KILLEEN KP, HOHMANN EL: Safety and immunogenicity of the phoP/phoQ-deleted Salmonella Ophi expressing H pylori urease in adult volunteers. Vaccine (2000) 18:449–459.
   Web of Science ®Google Scholar
• ANGELAKOPOULOS H, HOHMANN EL: Pilot study of phoP/phoQ-deleted Salmonella entericaserovar Typhimurium expressing Helicobacter pyloriurease in adult volunteers. Infect. Immun. (2000) 68:2135–2141.
   PubMed Web of Science ®Google Scholar
• BUMANN D, METZGER WG, MANSOURI E, PALME 0, WENDLAND M, HURWITZ R: Safety and immunogenicity of live recombinant Salmonella entericaserovar Typhi Ty2 la expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine (2001) 20:845–852.
   PubMed Web of Science ®Google Scholar
• KOTLOFF K, LOSONSKY G, WASSERMAN S, WALKER R: Safety and immunogenicity of a H py/orivaccine in human volunteers. In: Third Annual Winter H. pylori Workshop. Orlando, FL, USA (1999), Poster no. 63.
   Google Scholar
• RAPPUOLI R, PIZZA M, DOUCE G, DOUGAN G: Structure and mucosal adjuvanticity of cholera and Escherichia cob heat-labile enterotoxins. Immunol Today (1999) 20:493–500.
   PubMedGoogle Scholar
• MALFERTHEINER P, SCHULTZE V, DEL GIUDICE G et al.: Safety and immunogenicity of a three-component Helicobacter pylori vaccine Phase I study. Digestive Disease Week San Francisco, CA, USA (2002).
   Google Scholar
• GENTA RM: A year in the life of the gastric mucosa. Gastroenterology (2000) 119:252–254.
   PubMed Web of Science ®Google Scholar
• RUPNOW MFT, SHACHTER RD, DOUGLAS KO, PARSONNET J: Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine (2002) 20:879–885.
   Web of Science ®Google Scholar